Market revenue in 2023 | USD 328.0 million |
Market revenue in 2030 | USD 305.1 million |
Growth rate | -1% (CAGR from 2023 to 2030) |
Largest segment | Opioids |
Fastest growing segment | NSAIDs and Others |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Opioids was the largest segment with a revenue share of 25.95% in 2023. Horizon Databook has segmented the Russia cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
The incidence of cancer in the country is increasing. As per GLOBOCAN, the number of new cancer cases in Russia was 591,000 in 2020, which is expected to increase to 645,000 by 2030. Chemotherapy and radiation therapy are still commonly used for treatment of various types of cancer.
Large number of adverse effects associated with usage of traditional chemotherapy and radiation therapy is driving market growth. According to an article, the most commonly observed disease and treatment-related symptoms in gastric cancer patients after second line treatment include nausea/ vomiting in 75% patients and pain in around 74% patients.
According to the same article, antiemetics (~63%) and narcotic analgesics (~48%) were the most commonly used supportive care options. Rising penetration of biosimilars and declining prescription rates for opioids & ESAs are expected to impede market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Russia cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account